Bobbing on a sea of crises, bluebird's Nick Leschly sees his pay cut in half as the biotech prepares to split
It wasn’t so long ago that bluebird bio and CEO Nick Leschly were the darling of biotech, using a lentiviral vector approach that looked to change the game in gene therapy. But after a series of setbacks and a looming split of the business, Leschly has watched his star rapidly fall — and his pay to boot.
With bluebird on its way to a split between its gene therapy and oncology units, Leschly saw his pay in 2020 plummet to just over $6 million — a more than 50% cut from the previous year — as the biotech struggled through regulatory setbacks and an exodus of its leadership team, according to a proxy filing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,400+ biopharma pros reading Endpoints daily — and it's free.